Hyasynth Biologicals is a Montreal, Canada–based biotechnology company founded in 2014 that produces cannabinoids through fermentation using patent-pending yeast strains and enzymes. Its Better Cannabinoids technology enables scalable, low-cost production of major cannabinoids (THC, CBD, CBG) and rare/minor cannabinoids not typically accessible by plant cultivation. The company announced the first commercial sale of CBDa produced and extracted from yeast, a milestone tied to investor tranches. Hyasynth positions biosynthesis as pesticide-free, consistent, and lower-cost versus plant cultivation, with a smaller environmental footprint and suitability for food and pharmaceutical infrastructure. Investors named in the articles include SOSV/IndieBio, AngesQuebec and strategic investor Organigram Holdings Inc. Organigram also holds commercial purchase rights to Hyasynth’s production on discounted terms for a defined period.

Total raised

$3M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2020